High-Quality Tirzepatide CAS NO: 2023788-19-2 Manufacturer, Quotes

Tirzepatide is specially designed to target two key receptors in the body: glucose-dependent insulin secretagogue polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism of action enables Tirzepatide to simultaneously address multiple aspects of metabolic health, providing a comprehensive solution for people who have difficulty managing their weight.

Product Description

Tirzepatide is specially designed to target two key receptors in the body: glucose-dependent insulin secretagogue polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism of action enables Tirzepatide to simultaneously address multiple aspects of metabolic health, providing a comprehensive solution for people who have difficulty managing their weight.

Mechanism & Efficacy

Tirzepatide is a dual GLP-1/GIP receptor agonist designed to improve glycemic control, reduce body weight, and support overall metabolic health. It has been studied extensively in clinical trials for type 2 diabetes and obesity management.

Dosage & Clinical Use

Tirzepatide (brand names include Mounjaro®/Zepbound®) is used for glycemic control and weight management, administered as a once‑weekly subcutaneous injection. Available strengths typically include: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per dose, adjusted based on clinical response and tolerability.

Patents & Intellectual Property

Tirzepatide’s patent portfolio is extensive, involving multiple patents covering the peptide itself, formulations, methods of use, and dosing:

US12295987 – Method of using GIP/GLP‑1 co‑agonist for diabetes, expires Dec 30, 2041
US11357820, US12453755/756, US11918623 – Formulation and composition patents with expiry Jun 14, 2039
Additional US patents covering methods of glycemic control using optimized dosing regimens also expire through the 2030s.

Generic competition for tirzepatide is not expected until at least the mid‑2030s due to this broad patent coverage.

Quality & Compliance

Manufactured under cGMP standards, each batch is rigorously tested for purity, stability, and identity, ensuring research-grade quality suitable for preclinical and clinical studies.

Customer Service & Shipping

Our technical team is available for guidance on peptide handling, storage, and experimental design.

We provide temperature-controlled shipping with careful monitoring to ensure product stability during transit.

Therapeutic Areas

A Revolutionary Approach to Weight Management and Metabolic Health

In the evolving health and wellness landscape, the pursuit of effective weight management solutions has led to groundbreaking innovations. One such breakthrough is Tirzepatide, a cutting-edge dual-action therapy designed to support weight management and enhance metabolic health. With its unique mechanism of action, Tirzepatide has the potential to revolutionize the way we address obesity and related metabolic disorders.

Tirzepatide’s innovative design harnesses the body’s natural hormonal pathways to regulate appetite, enhance insulin sensitivity and improve glucose metabolism. By activating GIP and GLP-1 receptors, Tirzepatide helps:

1. Appetite Suppression: One of the main challenges in weight management is controlling hunger. Tirzepatide works by sending signals to the brain to reduce appetite, making it easier for people to stick to their dietary goals.
2. Enhance insulin sensitivity: Insulin resistance is a common problem in people with obesity and metabolic syndrome. Tirzepatide can improve the body’s response to insulin, promote blood sugar control, and reduce the risk of type 2 diabetes.
3. Promote weight loss: Clinical studies have shown that Tirzepatide can significantly reduce weight in obese patients. By suppressing appetite and improving metabolic function, users can achieve their weight loss goals more effectively.
4. Supports Overall Metabolic Health: In addition to weight loss, Tirzepatide improves metabolic health by lowering blood sugar levels, reducing fat accumulation, and improving lipid profiles. This holistic approach not only aids in weight management, but also provides long-term health benefits.

Outlook & Development

Tirzepatide is designed for adults who are obese or overweight, especially those who have not achieved the desired results through lifestyle changes alone. It is suitable for individuals seeking medically assisted weight management, especially those with related metabolic health issues.

As with any medical treatment, safety and effectiveness are of paramount importance. Tirzepatide has gone through rigorous clinical trials to ensure its effectiveness and safety. Patients can work closely with their healthcare provider to determine if Tirzepatide is the right choice for their weight management journey.

Tirzepatide represents a significant advancement in the field of weight management and metabolic health. By simultaneously targeting both the GIP and GLP-1 receptors, this dual-acting therapy offers a comprehensive solution for individuals seeking to improve their health and achieve sustainable weight loss. With Tirzepatide, the path to a healthier lifestyle is no longer just a dream, but a reality waiting to be embraced. Talk to your healthcare provider today to learn more about how Tirzepatide can support your weight management goals and enhance your overall health.

Frequently Asked Questions

What makes Tirzepatide different from traditional GLP-1 therapies?
Tirzepatide is a dual agonist targeting both GIP and GLP-1 receptors simultaneously. This combined action offers an integrated metabolic approach, leading to enhanced glycemic control and weight management outcomes.
How is Tirzepatide typically administered?
Tirzepatide is formulated for once-weekly subcutaneous injection, with dosing regimens adjusted according to patient response, starting from 2.5 mg up to 15 mg.
What are the primary target populations for Tirzepatide?
It is primarily intended for adults diagnosed with type 2 diabetes or individuals dealing with obesity and overweight conditions requiring medical metabolic intervention.
When are generic versions of Tirzepatide expected to enter the market?
Due to extensive patent coverage on formulations, method of use, and composition extending into 2039 and 2041, generic market entries are not anticipated until at least the mid-2030s.
What quality standards govern the supply and shipping of the peptide?
Every batch is produced under strict cGMP protocols and verified through identity, purity, and stability testing, backed by cold-chain monitored transit to maintain product stability.

Related Products